Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 18,500 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the sale, the chief executive officer owned 216,744 shares of the company’s stock, valued at approximately $7,963,174.56. This represents a 7.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.
• On Monday, February 23rd, Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50.

Vera Therapeutics Trading Up 6.7%

Shares of NASDAQ:VERA traded up $2.45 during trading on Wednesday, hitting $39.15. 1,186,027 shares of the company’s stock were exchanged, compared to its average volume of 1,148,606. Vera Therapeutics, Inc. has a 1-year low of $18.76 and a 1-year high of $56.05. The firm has a 50-day moving average price of $39.65 and a two-hundred day moving average price of $40.49. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The firm has a market cap of $2.79 billion, a P/E ratio of -7.07 and a beta of 0.96.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the business posted ($0.81) EPS. Equities analysts predict that Vera Therapeutics, Inc. will post -5.7 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Finally, Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Vera Therapeutics during the 3rd quarter worth approximately $911,000. Hudson Bay Capital Management LP boosted its holdings in shares of Vera Therapeutics by 47.4% in the third quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock valued at $12,804,000 after buying an additional 141,615 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Vera Therapeutics by 6.3% in the third quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock valued at $92,720,000 after buying an additional 189,545 shares during the period. AMI Asset Management Corp acquired a new position in shares of Vera Therapeutics in the fourth quarter valued at approximately $1,444,000. Finally, Candriam S.C.A. boosted its holdings in shares of Vera Therapeutics by 43.9% in the third quarter. Candriam S.C.A. now owns 427,189 shares of the company’s stock valued at $12,414,000 after buying an additional 130,248 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.